OncLive | Bringing the Global Oncology Community Together

The FDA has approved romiplostim for the treatment of pediatric patients aged ≥1 year with immune thrombocytopenia for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.Read More >>

EU Panel Backs Brentuximab Vedotin for Frontline CD30+ Hodgkin Lymphoma

Expert Evaluates Evolving Options in Relapsed/Refractory Myeloma

Trastuzumab Biosimilar CT-P6 Shows Comparable Efficacy at 2-Year Follow-up

Enzalutamide/Radium-223 Combo Shows Potential in mCRPC

T-DM1 May Provide Less-Toxic Option in Older HER2+ Breast Cancer Population

View More Stories >>

View Conference Coverage

2018 San Antonio Breast Cancer Symposium

2018 ASH Annual Meeting

2018 Ruesch Center Symposium

2018 Chemotherapy Foundation Symposium

2018 New York Lung Cancers Symposium

Dr. Konstantinopoulos on Immunotherapy in Gynecologic Cancers

Dr. De Censi Discusses Financial Benefit of Biosimilars

Dr. Gieschen on Patient Selection for Radiation in Prostate Cancer

Dr. Schmid on the Design and Findings of the KEYNOTE-173 Trial in TNBC

Dr. Shah Discusses the Criteria for Treatment Discontinuation in CLL

Dr. Paul Discusses the Pulmonologist's Role in Managing Patients With Lung Cancer

Dr. Siegel on Distinguishing Between Classes of Drugs in Myeloma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Tumor Mutational Burden in CRC

Efficacy and Safety of Immunotherapy for mCRC

TAS-102 Versus Regorafenib for Treating mCRC

Sidedness as Drivers of Treatment Decisions in CRC

Treatment Options for First- and Second-Line Left-Sided CRC

OncLive houses thousands of videos that provide updates and information.
See more Videos

CAR T-Cell Program Requirements

CAR T-Cell Program Feasibility in the Community Setting

Advice for Managing Patients With Thyroid Cancer

Emerging Therapies in Differentiated Thyroid Cancer

Precision Medicine in Differentiated Thyroid Cancer

Differentiated Thyroid Cancer: Sequencing of MTK Inhibitors

$RAI-Refractory Differentiated Thyroid Cancer: Lenvatinib$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

Expert Anticipates Cure in Acute Lymphoblastic Leukemia

Elias Jabbour, MD, discussed recent clinical trial results in acute lymphoblastic leukemia, the role of immunotherapy, and the biggest challenges facing the field.

View more >>>

Featured

Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin Lymphoma

Radhakrishnan Ramchandren MD, associate professor, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, discusses the North American results of the ECHELON-1 study in Hodgkin lymphoma.

View more >>>